News from neovasc inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 13, 2014, 07:00 ET

Neovasc Inc. Announces Financial Results For The Second Quarter 2014

--Reports Year-over-Year Revenue Growth of 58%-- --Tiara's Successful First Use Cases Highlighted at Industry Conference-- --Detailed Reducer Data...

Jul 07, 2014, 21:54 ET

Neovasc Inc. Provides Additional Comments on Lawsuit

NASDAQ: NVCN TSX: NVC VANCOUVER, July 7, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) has today been...

Jun 20, 2014, 07:00 ET

Neovasc Inc. Announces Receipt of Final Approval to Graduate to the TSX

NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 20, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) today...

Jun 19, 2014, 07:00 ET

Neovasc Inc. reports results of Annual General Meeting of Shareholders

NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 19, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) is...

Jun 12, 2014, 14:18 ET

Neovasc earns a spot in 2014 PROFIT 500 List

NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 12, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) is...

Jun 06, 2014, 16:15 ET

Neovasc Inc. provides initial comments on lawsuit

NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 6, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) has...

May 22, 2014, 07:00 ET

Neovasc Inc. reports financial results for first quarter 2014

NASDAQ: NVCN TSX VENTURE: NVC --Reports Year-over-Year Revenue Growth of 91%-- --Lists on NASDAQ Capital Market-- --Completes Canadian $25...

May 21, 2014, 10:45 ET

Positive First-In-Human Experience With Neovasc's Tiara™ Transcatheter Mitral Valve Presented at EuroPCR 2014

--Successful Results from First Compassionate Use Cases Demonstrate Feasibility and Ease of Procedure, with No Reported Safety Issues Related to...

May 16, 2014, 07:00 ET

Neovasc Inc. to begin trading on the NASDAQ Capital Market

NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, May 16, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) today...

Nov 13, 2013, 07:28 ET

Neovasc receives first US patent for its novel Tiara(TM) transcatheter mitral valve replacement technology

TSX Venture Exchange: NVC VANCOUVER, Nov. 13, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that the first patent covering the...

Nov 06, 2013, 07:28 ET

Neovasc Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Functional Capabilities in Patients with Refractory Angina

-Primary Efficacy Endpoint Achieved in Multicenter, Prospective, Randomized, Sham-Controlled Trial Assessing Novel Percutaneous Device in...

Oct 29, 2013, 07:28 ET

Neovasc Inc. Announces Publication of Positive Tiara™ Preclinical Data in the Journal JACC: Cardiovascular Interventions

--Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a...

Oct 24, 2013, 07:28 ET

Neovasc Inc. announces upcoming presentations at TCT 2013 scientific symposium

Neovasc's Tiara™ Program for the Transcatheter Treatment of Mitral Valve Disease Will Be Featured in Two Sessions VANCOUVER, Oct. 24, 2013...

Aug 15, 2013, 07:28 ET

Neovasc Inc. reports financial results for second quarter of 2013

--Year-over-Year Revenues Increased 71% from Robust Growth in Contract Manufacturing and Consulting Services Revenues-- TSX Venture Exchange:...

May 28, 2013, 07:30 ET

Neovasc Inc. Reports Financial Results for First Quarter of 2013

--Increased Year-over-Year Revenues by 17%, Driven by Growth in Contract Manufacturing and Consulting Services to Transcatheter Heart...

May 23, 2013, 07:30 ET

Positive Animal Data Presented at EuroPCR Sets Stage for Advancing Neovasc's Tiara(TM) Transcatheter Mitral Valve into Human Trials

-Longer-Term Animal Data Suggests Tiara Device for the Transcatheter Treatment of Mitral Valve Disease Appears Safe and Well Tolerated TSX...

May 21, 2013, 07:30 ET

Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angina Patients

-Initial Data from Patient Registries Shows the Reducer Significantly Improves Angina Scores at Six Months Post-Implantation- TSX Venture...

May 13, 2013, 07:25 ET

Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory Angina

-Full Data from COSIRA Trial Expected Around Year's End- -Initial Data from Reducer Patient Registries To Be Presented at EuroPCR 2013- TSX...

Apr 29, 2013, 07:25 ET

Neovasc Inc. reports financial results for 2012 year-end

--Grew Annual Revenues 49% Year-Over-Year to $7.8 Million-- --Significantly Advanced New Product Pipeline Programs-- TSX Venture Exchange:...

Feb 28, 2013, 07:30 ET

Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journal

-Trial Further Assessing Efficacy of Neovasc Reducer™ in Treatment of Refractory Angina Expected to Complete Patient Enrollment in Coming...